|Bid||239.64 x 800|
|Ask||240.18 x 900|
|Day's Range||237.89 - 248.54|
|52 Week Range||208.35 - 526.00|
|Beta (5Y Monthly)||0.93|
|PE Ratio (TTM)||47.83|
|Earnings Date||Aug 03, 2022 - Aug 08, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||365.13|
Subscribe to Yahoo Finance Plus to view Fair Value for ILMN
SAN DIEGO, May 18, 2022 /3BL Media/ - Illumina has been included for the first time on the 2022 100 Best Corporate Citizens list by 3BL Media, recognizing outstanding environmental, social, and gov...
Illumina (ILMN) subsidiary GRAIL's MCED blood test will be offered along with existing single cancer screenings to advance cancer care delivery through early detection.
Illumina, Inc. (NASDAQ: ILMN) a global leader in DNA sequencing and array-based technologies, and Allegheny Health Network (AHN), an integrated health system serving the Western Pennsylvania area, today announced a collaboration to evaluate the impact of in-house comprehensive genomic profiling (CGP) to enhance patient care.